Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

This study has been completed.

Study NCT00003593 Information provided by National Cancer Institute (NCI)

First Received: November 1, 1999 Last Updated: July 23, 2008 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Leukemia
Myelodysplastic Syndromes

Additional conditions recognized in this trial

Down Syndrome
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Preleukemia
Syndrome

More general conditions related to this trial

Abnormalities, Multiple
Bone Marrow Diseases
Chromosome Disorders
Congenital Abnormalities
Disease
Genetic Diseases, Inborn
Hematologic Diseases
Mental Retardation
Neoplasms
Neoplasms by Histologic Type
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Pathologic Processes
Precancerous Conditions

Interventions listed in this trial

asparaginase
cytarabine
daunorubicin hydrochloride
methotrexate
therapeutic hydrocortisone
thioguanine

Additional drug interventions recognized in this trial

Cortisol succinate
Daunorubicin
Hydrocortisone
Hydrocortisone acetate

Sponsors listed in this trial

Children's Oncology Group
National Cancer Institute (NCI)

Back to top of Main Content